• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Incyte to Report First Quarter Financial Results

    4/10/25 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $INCY alert in real time by email

    Incyte (NASDAQ:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 29, 2025.

    The schedule for the press release and conference call/webcast is as follows:

    • Q1 2025 Press Release: April 29, 2025 at 7:00 a.m. ET
    • Q1 2025 Conference Call: April 29, 2025 at 8:00 a.m. ET
    • Domestic Dial-In Number: 877-407-3042
    • International Dial-In Number: 201-389-0864
    • Conference ID Number: 13753168

    If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13753168.

    The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

    About Incyte

    A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

    For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250410696945/en/

    Media

    [email protected]



    Investors

    [email protected]

    Get the next $INCY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INCY

    DatePrice TargetRatingAnalyst
    6/16/2025$107.00Hold → Buy
    Stifel
    3/18/2025Buy → Neutral
    Guggenheim
    3/18/2025Outperform → Mkt Perform
    William Blair
    12/17/2024$77.00Neutral
    UBS
    10/29/2024$68.00 → $90.00Neutral → Buy
    BofA Securities
    10/1/2024$84.00Outperform
    Wolfe Research
    9/18/2024$83.00 → $74.00Buy → Hold
    Truist
    7/2/2024$52.00 → $48.00Market Perform → Underperform
    BMO Capital Markets
    More analyst ratings

    $INCY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for JAKAFI issued to INCYTE CORP

      Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling

      9/28/21 5:20:01 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • FDA Approval for JAKAFI issued to INCYTE CORP

      Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy

      9/23/21 5:11:12 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • FDA Approval for OPZELURA issued to INCYTE CORP

      Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

      9/22/21 11:16:23 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    SEC Filings

    See more
    • SEC Form 144 filed by Incyte Corp.

      144 - INCYTE CORP (0000879169) (Subject)

      7/3/25 2:46:56 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 filed by Incyte Corp.

      S-8 - INCYTE CORP (0000879169) (Filer)

      7/2/25 4:00:42 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte Corp. filed SEC Form 8-K: Leadership Update

      8-K - INCYTE CORP (0000879169) (Filer)

      6/27/25 4:54:02 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Incyte upgraded by Stifel with a new price target

      Stifel upgraded Incyte from Hold to Buy and set a new price target of $107.00

      6/16/25 7:42:04 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte downgraded by Guggenheim

      Guggenheim downgraded Incyte from Buy to Neutral

      3/18/25 7:52:49 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte downgraded by William Blair

      William Blair downgraded Incyte from Outperform to Mkt Perform

      3/18/25 7:52:29 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Incyte Corporation (NASDAQ:INCY) announced today equity inducement awards grants to Bill Meury in connection with his appointment as the Company's new President and Chief Executive Officer. The awards are made pursuant to the Company's 2024 Inducement Stock Incentive Plan and were approved by the compensation committee of the Company's Board of Directors as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). As an inducement material to his employment and in lieu of the annual equity awards the Company typically grants in July of each year, Mr. Meury received, with a grant and vesting commencement date of

      7/2/25 4:30:00 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

      - Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO - Hervé Hoppenot to retire after 11 years of leading Incyte through major expansion - Julian Baker elected Chairman of the Board of Directors Incyte (NASDAQ:INCY) today announced that the Company's Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors, effective immediately. Bill Meury succeeds Hervé Hoppenot who will retire from the Company after 11 years of service. Mr. Hoppenot will serve as an advisor to the CEO and will remain as a

      6/26/25 7:30:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis

      Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura®), a topical Janus kinase (JAK) inhibitor, for the treatment of children 2-11 years old with mild to moderate atopic dermatitis (AD). The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to September 19, 2025. The FDA extended the PDUFA action date to allow time to review additional chemistry, manufacturing and controls (CMC) data on the 0.75% strength submitted by Incyte in response to a recent FDA information request. "Atopic dermatitis (AD) is a chronic

      6/20/25 4:30:00 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Leadership Updates

    Live Leadership Updates

    See more
    • Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

      - Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO - Hervé Hoppenot to retire after 11 years of leading Incyte through major expansion - Julian Baker elected Chairman of the Board of Directors Incyte (NASDAQ:INCY) today announced that the Company's Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors, effective immediately. Bill Meury succeeds Hervé Hoppenot who will retire from the Company after 11 years of service. Mr. Hoppenot will serve as an advisor to the CEO and will remain as a

      6/26/25 7:30:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

      Mechelen, Belgium; 12 June 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director. Dr. Schaffert replaces Dr. Rajesh Parekh who stepped down on 10 June 2023. After an extraordinary 27-year career at Novartis in various global roles, including commercialization, market access, investor relations, business development & licensing, acquisitions and company integration, Dr. Schaffert retired in 2022 as President of Novartis Oncology and Member of the Novartis Executive Committee. In that role, Dr. Schaffert ran a global $15 billion business acr

      6/12/23 4:01:00 PM ET
      $GLPG
      $INCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Incyte Names New Member to Its Board of Directors

      Incyte (NASDAQ:INCY) announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors. "On behalf of the Incyte Board of Directors, I am happy to welcome Susanne. Her extensive commercial, development and industry experience will greatly complement our Board and we look forward to Susanne's contributions to our continued growth and future success," said Hervé Hoppenot, Chief Executive Officer, Incyte. "I am very excited for the opportunity to join the Incyte Board of Directors and helping the organization in its commitment to leading scientific innovation and developing new medicines for patients in need. I look forward to being part of this dynamic Company

      10/4/22 8:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Human Resources Swain Paula J covered exercise/tax liability with 6,285 shares, decreasing direct ownership by 6% to 101,059 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/7/25 4:56:19 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Principal Accounting Officer Tray Thomas covered exercise/tax liability with 897 shares, decreasing direct ownership by 4% to 21,106 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/7/25 4:48:58 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • EVP & Chief Medical Officer Stein Steven H covered exercise/tax liability with 12,714 shares, decreasing direct ownership by 10% to 112,418 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/7/25 4:48:25 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Financials

    Live finance-specific insights

    See more
    • Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

      Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic response with the majority (82%) realizing a complete response A reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic response Initial results demonstrate a favorable safety profile – no dose limiting toxicit

      6/15/25 3:15:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

      Late-breaking oral presentation will highlight new data from a trial of INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody, in patients with essential thrombocythemia (ET) Incyte to host an in-person analyst and investor event highlighting the mutCALR data at EHA on Sunday, June 15, 2025, from 6:00 - 7:30 a.m. EDT (12:00 - 1:30 p.m. CEST) Incyte (NASDAQ:INCY) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 – 15, 2025, in Milan. "We're looking forward to presenting new data from across our hematology/oncology portfolio at the 20

      6/3/25 10:30:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

      – Total revenues of $1,053 million in the first quarter (Q1'25) (+20% Y/Y); total product revenues of $922 million in Q1'25 (+26%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to a new range of $2,950 - $3,000 million from $2,925 - $2,975 million – Opzelura® (ruxolitinib) cream net product revenues of $119 million in Q1'25 (+38% Y/Y) – Niktimvo™ (axatilimab-csfr) net product revenues of $14 million in the first two months of U.S. launch demonstrating strong commercial execution and high patient need – New, 18-week data from ongoing Phase 3 study of povorcitinib in hidradenitis suppurativa (HS) demonstrates

      4/29/25 7:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Incyte Corp.

      SC 13G - INCYTE CORP (0000879169) (Subject)

      10/17/24 9:39:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Incyte Corp.

      SC 13D/A - INCYTE CORP (0000879169) (Subject)

      6/14/24 6:23:05 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Incyte Corp. (Amendment)

      SC 13D/A - INCYTE CORP (0000879169) (Subject)

      5/13/24 6:06:33 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care